Navigation Links
Cell Therapeutics Amends 'Modified Dutch Auction' Tender Offer for up to $89.2 million of Its Outstanding Convertible Notes
Date:5/18/2009

and the consideration within the specified range of Exchange Consideration at which they wish to tender such Notes.

As of May 18, 2009, approximately $118.9 million aggregate principal amount of the Notes was outstanding. The Exchange Offer is conditioned upon a minimum of $83,260,100 aggregate principal amount of Notes being validly tendered and not withdrawn, as well as certain other terms and conditions described in the Company's Offer to Exchange, dated May 12, 2009 (as supplement May 19, 2009, the "Offer to Exchange"), the related Amended and Restated Letter of Transmittal, and other related Exchange Offer materials (which collectively, as may be amended, restated, supplemented, or otherwise modified from time to time, constitute the "Exchange Offer Documents").

The Exchange Offer is scheduled to expire at 5:00 p.m., New York City time, on Wednesday, June 10, 2009, unless the Exchange Offer is extended. Tendered Notes may be withdrawn at any time on or prior to the expiration date of the Exchange Offer.

CTI is conducting the Exchange Offer in order to reduce the principal amount of its outstanding indebtedness. CTI believes that reducing its outstanding indebtedness is necessary in order for its business to operate in light of its current asset base and revenue prospects.

If the aggregate amount of Notes validly tendered and not properly withdrawn on or prior to the expiration date at or below the Exchange Consideration exceeds the amount CTI is offering to exchange, CTI will accept for payment the Notes that are validly tendered and not properly withdrawn from the Exchange Offer at or below the Exchange Consideration on a pro rata basis from among the tendered Notes.

The financial advisor for the Exchange Offer is Piper Jaffray & Co., the information agent for the Exchange Offer is Georgeson Inc. and the depositary for the Exchange Offer is U.S. Bank National Associati
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Nile Therapeutics CD-NP Clinical Program for Acute Heart Failure Released From Clinical Hold by FDA
2. Fate Therapeutics Granted Exclusive License for Stem Cell Modulators by Childrens Hospital Boston and Massachusetts General Hospital
3. Cell Therapeutics Closes Italian Facility, Reduces Headcount and Expects to Cut $14 Million in Operating Expenses
4. Cell Therapeutics, Inc. (CTI) to Present at 2009 BIO International Convention
5. Orexigen(R) Therapeutics to Present at Upcoming Meetings
6. Prospect Therapeutics, Inc. Assigns All Its Assets to Joseph F. Finn, Jr., C.P.A. for the Benefit of Its Creditors
7. Cell Therapeutics to Exchange up to $89.2 million of Its Outstanding Convertible Notes in a Modified Dutch Auction Tender Offer
8. PTC Therapeutics and Spinal Muscular Atrophy Foundation Announce $8.5 Million Small Molecule Development Collaboration
9. Orexigen(R) Therapeutics Announces Jay Hagan as Senior Vice President, Corporate Development and Strategy
10. Amicus Therapeutics to Present at the Bank of America and Merrill Lynch 2009 Health Care Conference on May 13, 2009
11. Orexigen(R) Therapeutics to Speak at Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... Dec. 15, 2014  Ascendis Pharma A/S, a ... to address significant unmet medical needs, today announced ... 2 pediatric study to evaluate once-weekly TransCon Growth ... GHD.  This interim analysis consists of 25 patients, ... in the study, completing all six months of ...
(Date:12/13/2014)... Washington, USA, and TAICHUNG, Taiwan (PRWEB) December 12, 2014 ... rise, despite less rosy indicators in overall global economic ... society for optics and photonics , said in a ... International Conference) on 5 December at the National Chung ... solar energy, which is being integrated into future energy ...
(Date:12/13/2014)... 2014 Research and Markets ( ... "Glucose Sensors: the Next Generation" report ... http://photos.prnewswire.com/prnh/20130307/600769 The convergence of small-scale ... hope for a better future to millions of ... measure glucose levels accurately and reliably have the ...
(Date:12/12/2014)... Pittcon is pleased to announce the ... 2,000 technical presentations offered in symposia, oral sessions, ... covers a wide range of applications such as, ... environmental, food science, fuels/energy, genomics, lab management, materials ... Technical Program begins on Sunday, March 8 and ...
Breaking Biology Technology:Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 2Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 3Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 4Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 5Glucose Sensors: the Next Generation 2Glucose Sensors: the Next Generation 3Pittcon Announces a Diverse 2015 Technical Program - Renowned Speakers, Special Symposia and Co-programming 2Pittcon Announces a Diverse 2015 Technical Program - Renowned Speakers, Special Symposia and Co-programming 3
... /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.,("Oncolytics") (TSX:ONC, NASDAQ:ONCY) ... to pursue a pivotal (Phase II/III) randomized ... in refractory,patients with head and neck cancers. ... results by the Company,s Board of Directors ...
... BOZEN, Italy, November 4 Health-Robotics today,announced ... strategic partnership with,Arabian Health Care Supply Corporation ... IV Solution provider within the Gulf,Cooperation Council ... cost-effectively automate the preparation of life-critical hazardous,and ...
... team up in specialty biologics development, TORONTO ... and,Therapure BioPharma Inc. have agreed to partner in ... for cancer treatments, with a goal of,advancing the ... a,marketing partner to add to its portfolio of ...
Cached Biology Technology:Oncolytics Biotech Inc. Announces Decision to Pursue Phase II/III Pivotal Clinical Trial 2Health Robotics Announces Contract for its CytoCare(TM) and IV Station(TM) Robots With Arabian Health Care Supply Corporation 2Health Robotics Announces Contract for its CytoCare(TM) and IV Station(TM) Robots With Arabian Health Care Supply Corporation 3Health Robotics Announces Contract for its CytoCare(TM) and IV Station(TM) Robots With Arabian Health Care Supply Corporation 4Therapure Biopharma Inc. announces collaboration with BioVectra Inc. 2
(Date:11/21/2014)... Nov. 19, 2014  Earlier this year Donald ... College, and one of the most prolific inventors in ... are transmitted from Smartphones to third party agencies. Spector ... has one of the earliest known patents in this ... in the military, child care, elder care and hospital ...
(Date:11/21/2014)... , Nov. 20, 2014   Atmel® Corporation ... in microcontroller (MCU) and touch technology solutions, today launched ... sensors with the widest V cc range ... temperature accuracy and faster I 2 C bus communication ... serial EEPROM memory making them ideal for consumer, industrial, ...
(Date:11/18/2014)... Nov. 17, 2014 The Parenteral Drug Association (PDA) ... agencies will speak and at least seven more will participate ... the Omni Shoreham Hotel in Washington D.C. ... to have significant support from the regulatory agencies in ... in our effort to help advance the use ...
Breaking Biology News(10 mins):Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2
... the challenges of increasing demands for food from a growing ... in the journal Science ., The goal of sustainable ... the article in the journal,s Policy Forum by lead authors ... of Oxford. They say this would minimise the pressure on ...
... Large-scale network organisation in the avian forebrain Birds ... years. So it,s hardly surprising that under a microscope, the ... a mammal. Nevertheless, birds have been shown to be remarkably ... puzzles. How is it that both kinds of brain are ...
... COLLEGE STATION Texas A&M University System scientists from ... science have developed a new medium for the cultivation ... of lactobacilli metabolism can help improve feed efficiency ... the researchers. "Lactobacilli are normal residents of the ...
Cached Biology News:The balancing act of producing more food sustainably 2The balancing act of producing more food sustainably 3Frontiers news briefs: July 4 2Frontiers news briefs: July 4 3Frontiers news briefs: July 4 4Frontiers news briefs: July 4 5Frontiers news briefs: July 4 6Newly developed medium may be useful for human health, biofuel production, more 2
Rabbit polyclonal to FLIP ( Abpromise for all tested applications). entrezGeneID: 8837 SwissProtID: O15519...
Ly-49C and Ly-49I Biotin Anti-Mouse clone 5E6, Isotype Mouse IgG 2a , kappa, 0.1 mg Consult technical datasheet for details....
Dog polyclonal to Porcine Pancreatic Islets of Langerhans Cells ( Abpromise for all tested applications). Antigen: Tissue / cell preparation (Pig): Sonicated crude membrane fraction of porcine p...
Anti-Cohesin (Scc1/Rad21) Monoclonal Antibody Research Focus: signal transduction Storage: -20C Shipping Temperature: +4C...
Biology Products: